Search research articles
Contact Us
Filters
Showing results (11-20 of 79) with videos related to
Page
of 8
Sort By:
Clinical Pharmacology and Therapeutics
|
January 20, 2009
From darkness to light with biomarkers in early clinical trials of cancer drugs
C P Carden, U Banerji, S B Kaye, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
April 12, 2017
Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician
S Lheureux, C Denoyelle, P S Ohashi, et al.
British Journal of Cancer
|
September 20, 2006
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
G Attard, D Sarker, A Reid, et al.
Experimental Hematology
|
January 21, 2000
Granulocyte macrophage colony-stimulating factor and interleukin-3 regulate chemokine and chemokine receptor expression in bone marrow macrophages
D I Jarmin, R J Nibbs, T Jamieson, et al.
Prostate Cancer and Prostatic Diseases
|
September 28, 2016
Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer
G Sonpavde, G R Pond, A J Templeton, et al.
European Radiology
|
June 29, 2011
Assessing response in bone metastases in prostate cancer with diffusion weighted MRI
C Messiou, D J Collins, S Giles, et al.
Skeletal Radiology
|
November 26, 2013
Use of apparent diffusion coefficient as a response biomarker in bone: effect of developing sclerosis on quantified values
C Messiou, D J Collins, V A Morgan, et al.
British Journal of Cancer
|
August 17, 2000
Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT)
J S de Bono, J Paul, A Simpson, et al.
Journal of Clinical Pathology
|
December 11, 2008
Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity
G Attard, C Jameson, J Moreira, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 12, 2010
All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer
F A W Coumans, C J M Doggen, G Attard, et al.
Page
of 8
Search research articles
Search
Showing results (11-20 of 79) with videos related to
Sort By:
Page
of 8
Clinical Pharmacology and Therapeutics
|
January 20, 2009
From darkness to light with biomarkers in early clinical trials of cancer drugs
C P Carden, U Banerji, S B Kaye, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
April 12, 2017
Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician
S Lheureux, C Denoyelle, P S Ohashi, et al.
British Journal of Cancer
|
September 20, 2006
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
G Attard, D Sarker, A Reid, et al.
Experimental Hematology
|
January 21, 2000
Granulocyte macrophage colony-stimulating factor and interleukin-3 regulate chemokine and chemokine receptor expression in bone marrow macrophages
D I Jarmin, R J Nibbs, T Jamieson, et al.
Prostate Cancer and Prostatic Diseases
|
September 28, 2016
Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer
G Sonpavde, G R Pond, A J Templeton, et al.
European Radiology
|
June 29, 2011
Assessing response in bone metastases in prostate cancer with diffusion weighted MRI
C Messiou, D J Collins, S Giles, et al.
Skeletal Radiology
|
November 26, 2013
Use of apparent diffusion coefficient as a response biomarker in bone: effect of developing sclerosis on quantified values
C Messiou, D J Collins, V A Morgan, et al.
British Journal of Cancer
|
August 17, 2000
Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT)
J S de Bono, J Paul, A Simpson, et al.
Journal of Clinical Pathology
|
December 11, 2008
Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity
G Attard, C Jameson, J Moreira, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 12, 2010
All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer
F A W Coumans, C J M Doggen, G Attard, et al.
Page
of 8